St. Luke's Hospital
Main Number: 314-434-1500 Emergency Dept: 314-205-6990 Patient Billing: 888-924-9200
Find a Physician Payment Options Locations & Directions
Follow us on: facebook twitter Mobile Email Page Email Page Print Page Print Page Increase Font Size Decrease Font Size Font Size
Pulmonary Rehabilitation
Pulmonary Function Testing
Respiratory Therapy
Pulmonary Physicians
The Lung Research Center
St. Luke's Pulmonary Doctors in the News
America's 50 Best Hospitals
Spirit of Women
Community Health Needs Assessment

Pulmonary Services


What is Bronchiectasis? Bronchiectasis (bron-key-ECK-tah-sis) is a lung condition where your bronchi get too wide and mucus builds up in them. Your bronchi are medium-sized airways (tubes that carry air in and out of your lungs). Your lungs make mucus to trap and remove germs and irritants that you breathe in. The mucus made in your lungs is also called phlegm (flem). Your airways are lined with ciliated cells that help move the mucus out of your lungs. The cilia (SIL-ee-ah) are fine, hair-like structures on the cells that move back and forth. These special cells sweep the mucus upward in your airways to move it out of your lungs. With Bronchiectasis, your lungs get damaged and cannot clear out the mucus the way they should. The mucus stays in the airways and germs grow in it and scar, making it harder for you to move air through them. Treatment is aimed at preventing more damage from infections.

Symptoms include:
Frequent Coughing
Chest Congestion
Mucus Build Up
Frequent Chest Infections

Bronchiectasis Clinical Research Trials
Currently Enrolling:

BAYQ3939: A Prospective, Non-randomized, Open-label, Non-controlled, Multicenter Study to Evaluate the Safety, Efficacy and Pharmacokinetics/ Pharmacodynamics of BAYQ3939 (400 mg BID and 400 mg TID) in Hospitalized Patients With Severe Bacterial Pneumonia or Bacterial Pneumonia With a Poor Response to Other Antimicrobials.

Purpose: The main objective of this study is to investigate the safety, pharmacokinetics (PK) and the relationship between PK and pharmacodynamics (Minimum Inhibitory Concentration [MIC] and Mutant Prevention Concentration [MPC]) of intravenous BAYQ3939 (400 mg BID and 400 mg TID) in hospitalized patients with severe pneumonia or patients who did not respond to other antibiotics used for the treatment of bacterial pneumonia. In addition, the efficacy of the ciprofloxacin, in terms of clinical response and microbiological response, will be investigated, but as a secondary endpoint. Participation could last up to 58 weeks.

For All Studies:
Qualified participants will receive study-related care, study-related exams and study-related medication at no cost. Participants may be compensated for their time and travel.

If you are interested in participating in a study or would like more information, register now or contact The Lung Research Center at 314-439-LUNG (5864) or email:

Dr. LaBelle: Bronchiectasis

Back  |  Top
About Us
Contact Us
Locations & Directions
Quality Reports
Annual Reports
Honors & Awards
Community Health Needs

Brain & Spine
Sleep Medicine
Urgent Care
Women's Services
All Services
Patients & Visitors
Locations & Directions
Find a Physician
Tour St. Luke's
Patient & Visitor Information
Contact Us
Payment Options
Financial Assistance
Send a Card
Mammogram Appointments
Health Tools
My Personal Health
Spirit of Women
Health Information & Tools
Clinical Trials
Health Risk Assessments
Employer Programs -
Passport to Wellness

Classes & Events
Classes & Events
Spirit of Women
Donate & Volunteer
Giving Opportunities
Physicians & Employees
For Physicians
Remote Access
Medical Residency Information
Pharmacy Residency Information
Physician CPOE Training
St. Luke's Hospital - 232 South Woods Mill Road - Chesterfield, MO 63017 Main Number: 314-434-1500 Emergency Dept: 314-205-6990 Patient Billing: 888-924-9200
Copyright © St. Luke's Hospital Website Terms and Conditions  |  Privacy Policy  |  Patient Notice of Privacy Policies PDF Sitemap St. Luke's Mobile